– SWEDEN, Uppsala – LIDDS AB (FRA: 5LD) today announced that Dr. Nina Herne, Ph.D. will assume the role of CEO, effective April 19, 2021, succeeding Monica Wallter who remains as CEO until Nina is in place, and will continue as a Senior Advisor.
“I am really excited to have Nina on board with us at LIDDS. Her experience and energy will be very important assets now as we accelerate our journey towards the Main Market, including expansion of the organisation”, said Board Chairman, Jan Törnell. “We will drive our business development activities with continued great effort and build a strong pipeline of valuable projects. Nina has an excellent background to fulfil LIDDS needs for the future.”
Monica Wallter has excellently led LIDDS since 2015 through successful clinical trials with Liproca and NZ-DTX and converted LIDDS from a one-project company to a platform company based on the NanoZolid technology. LIDDS has signed licensing agreements and increased its market cap more than fourfold during her time as CEO.
“LIDDS is embarking on the next phase with a strong pipeline of new projects as well as a planned transfer to Main Market. It is after five exciting years, time for me to hand over my operational duties, and the long-term responsibility of building value for our shareholders”, said Monica Wallter.
About Dr. Nina Herne
Nina Herne has successfully held multiple senior positions in global pharmaceutical companies, most recently at Chiesi Group where she built a biotech operation and managed the company’s Swedish R&D site. Nina brings a wide range of experience from business development and licensing, R&D, operations, strategy development, and international stakeholder management from smaller organizations like Zymenex (Managing Director for Sweden and Denmark) and NeuroNova, as well as larger companies like Chiesi, SOBI, and Novozymes.
“It is with great expectation that I take on my new role and lead LIDDS through its next phase,” said Nina Herne. “I strongly believe in the company’s technology and see a significant value in its project portfolio. I specifically look forward to continuing the development of our immuno-oncology projects where my previous experience will be of particular value.”
She holds a Ph.D. in Immunology and an Executive MBA from Stockholm School of Economics.
About LIDDS
LIDDS AB is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid. NanoZolid is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in the clinical and preclinical phase for cytostatics and immuno-active agents. LIDDS shares are listed on Nasdaq First North Growth Market.
For more information: https://liddspharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.